Four things to know:
- Biogen is aiming to enroll more than 1,300 people with early Alzheimer’s in the study.
- The drugmaker plans to submit the study’s final protocol for review to the FDA in March, with patient screening beginning in May.
- Biogen predicts the study will take about four years to complete, meaning the drugmaker won’t have data until 2026.
- The study is a post-marketing requirement of the FDA’s accelerated approval pathway.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
